TABLE 1.
Patient characteristics
|
Total enrolled N = 1126 |
Passageable tumors N = 298 |
Discontinued N = 476 |
Not yet assessable N = 326 |
P‐value | |
|---|---|---|---|---|---|
| Age (median, range) | 61 (5‐91) | 61 (12‐88) | 61 (12‐91) | 61 (5‐87) | .406 |
| Sex (M/F, %) | 545/581 (48%/52%) | 152/146 (51%/49%) | 236/240 (50%/50%) | 139/187 (43%/57%) | .699 |
| Smoking history (Yes/No/NA, %) | 574/548/4 (51%/49%/0%) | 156/142/0 (52%/28%/0%) | 243/232/1 (51%/49%/0%) | 162/162/2 (50%/50%/0%) | .725 |
| Stage (I‐II/III, IV, recurrence/NE, %) | 355/667/104 (32%/59%/9%) | 64/218/16 (21%/73%/5%) | 143/285/48 (30%/60%/10%) | 147/152/27 (45%/47%/8%) | .002 |
| Prior‐treatment history (Yes/No, %) | 1023/103 (91%/9%) | 266/32 (89%/11%) | 426/50 (90%/10%) | 313/13 (96%/4%) | .918 |
| Prior‐surgery (Yes/No, %) | 892/232 (79%/21%) | 227/70 (76%/24%) | 372/103 (78%/22%) | 288/38 (88%/12%) | .541 |
| Prior‐radiotherapy (Yes/No, %) | 149/975 (13%/87%) | 45/252 (15%/85%) | 63/412 (13%/87%) | 37/289 (11%/89%) | .462 |
| Prior‐chemotherapy (Yes/No, %) | 339/787 (30%/70%) | 105/193 (35%/65%) | 128/348 (27%/73%) | 89/237 (27%/73%) | .014 |
| Prior‐chemotherapy line (1st line/2nd line/3rd line ‐, %) | 145/77/117 (43%/23%/32%) | 40/23/42 (38%/22%/40%) | 52/28/48 (41%/22%/38%) | 44/21/24 (48%/24%/28%) | |
| Prior‐cytotoxic chemotherapy (n, %) | 292 (86%) | 95 (90%) | 103 (80%) | 79 (89%) | |
| Prior‐tyrosine kinase inhibitor (n, %) | 84 (25%) | 23 (22%) | 43 (33%) | 15 (17%) | |
| Prior‐immune checkpoint inhibitor (n, %) | 42 (12%) | 14 (13%) | 18 (14%) | 9 (10%) | |
| Prior‐investigational new drug (n, %) | 22 (6%) | 7 (7%) | 8 (6%) | 7 (8%) | ‐ |
| Specimen type (Biopsy/Surgical) | 343/783 (30%/70%) | 99/199 (33%/67%) | 151/325 (32%/68%) | 67/259 (21%/79%) | .664 |
| Time to transplantation (Days, average, range) | 1.25 (0‐11) | 1.03 (0‐5) | 1.27 (0 ‐ 11) | 1.40 (0‐10) | .005 |